The stock price of Replimune Group Inc (NASDAQ: REPL) has plunged by -3.08 when compared to previous closing price of 9.75, but the company has seen a -0.58% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-06 that WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Is It Worth Investing in Replimune Group Inc (NASDAQ: REPL) Right Now?
The stock has a 36-month beta value of 0.62. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for REPL is 62.53M, and at present, short sellers hold a 13.60% of that float. On June 26, 2025, the average trading volume of REPL was 1.17M shares.
REPL’s Market Performance
REPL stock saw an increase of -0.58% in the past week, with a monthly gain of 13.17% and a quarterly increase of -11.60%. The volatility ratio for the week is 3.89%, and the volatility levels for the last 30 days are 3.84% for Replimune Group Inc (REPL). The simple moving average for the last 20 days is -1.60% for REPL stock, with a simple moving average of -14.76% for the last 200 days.
Analysts’ Opinion of REPL
ROTH MKM, on the other hand, stated in their research note that they expect to see REPL reach a price target of $17. The rating they have provided for REPL stocks is “Buy” according to the report published on August 28th, 2024.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $44 in the report published on April 17th of the previous year.
REPL Trading at 6.34% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.41% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Astley-Sparke Philip, who sale 32,279 shares at the price of $8.06 back on May 20 ’25. After this action, Astley-Sparke Philip now owns 1,405,071 shares of Replimune Group Inc, valued at $260,169 using the latest closing price.
Xynos Konstantinos, the Chief Medical Officer of Replimune Group Inc, sale 7,952 shares at $8.06 during a trade that took place back on May 20 ’25, which means that Xynos Konstantinos is holding 146,933 shares at $64,093 based on the most recent closing price.
Stock Fundamentals for REPL
The total capital return value is set at -0.47. Equity return is now at value -62.58, with -47.60 for asset returns.
Currently, EBITDA for the company is -261.63 million with net debt to EBITDA at 1.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.95.
Conclusion
To sum up, Replimune Group Inc (REPL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
